Sign in

Andy Chin

Research Analyst at Wolfe Research

Andy Chin is an Equity Research Analyst at Wolfe Research, specializing in coverage of the technology hardware and semiconductor sectors, including companies such as Apple Inc., Dell Technologies, and Cisco Systems. He has established a strong performance track record, with his calls being ranked on TipRanks and recognized for generating above-market returns and high accuracy scores. Beginning his career at J.P. Morgan as an associate analyst in 2013, Chin joined Wolfe Research in 2018 and has steadily advanced to his current role through demonstrated analytical rigor and insightful sector coverage. He holds FINRA registration with Series 7, 63, 86, and 87 securities licenses, underlining his professional credentials and regulatory compliance.

Andy Chin's questions to INSMED (INSM) leadership

Question · Q1 2025

An analyst on behalf of Andy Chin asked if the recent patient death in Sarepta's DMD gene therapy trial has influenced Insmed's development strategy for its own gene therapy programs.

Answer

CEO William Lewis explained that Insmed's strategy, which uses an intrathecal delivery approach, inherently has safety benefits by reducing the required dose and bypassing the first-pass liver effect. He noted this approach has shown good transduction in preclinical models. He emphasized that the company has taken extra time on its gene therapy programs due to industry-wide safety concerns and has not seen any similar issues in its own work.

Ask follow-up questions

Fintool

Fintool can predict INSMED logo INSM's earnings beat/miss a week before the call

Let Fintool AI Agent track Andy Chin for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free